Total CF product revenues, net — Total revenues
Vertex Pharmaceuticals Total CF product revenues, net — Total revenues increased by 6.2% to $2.92B in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market penetration, patient adherence, or successful expansion of the eligible patient population, while a decrease may signal increased competition, patent expirations, or market saturation.
Detailed definition
This metric represents the aggregate net sales generated from the company's portfolio of cystic fibrosis therapeutic pro...
Peer comparison
Comparable to core therapeutic franchise revenues in other specialized biopharmaceutical companies, often evaluated against total revenue concentration to assess product dependency risk.
vrtx_segment_total_cf_product_revenues_net_total_revenuesHistorical Data
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $2.74B | $2.92B |
| QoQ Change | — | +6.2% |
| YoY Change | — | +6.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's total cf product revenues, net — total revenues?
- Vertex Pharmaceuticals (VRTX) reported total cf product revenues, net — total revenues of $2.92B in Q1 2026.
- What does total cf product revenues, net — total revenues mean?
- The total net revenue generated from the sale of all cystic fibrosis treatment products.